Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor-κB to the rescue?

Cardiovasc Res. 2020 May 1;116(6):1092-1094. doi: 10.1093/cvr/cvz344.

Authors

Kirsten Theresa Nijholt¹, Berend Daan Westenbrink¹, Rudolf Allert de Boer¹

Affiliation

¹ Department of Cardiology, University Medical Center Groningen, University of Groningen, AB 31, PO Box 30.001, Groningen 9700 RB, The Netherlands.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cardiomyopathies*
Doxorubicin / adverse effects
Humans
Mitochondrial Permeability Transition Pore
NF-kappa B*
Peptidyl-Prolyl Isomerase F

Substances

Peptidyl-Prolyl Isomerase F
Mitochondrial Permeability Transition Pore
NF-kappa B
Doxorubicin